JP2011500780A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500780A5
JP2011500780A5 JP2010530564A JP2010530564A JP2011500780A5 JP 2011500780 A5 JP2011500780 A5 JP 2011500780A5 JP 2010530564 A JP2010530564 A JP 2010530564A JP 2010530564 A JP2010530564 A JP 2010530564A JP 2011500780 A5 JP2011500780 A5 JP 2011500780A5
Authority
JP
Japan
Prior art keywords
bosentan
crystal form
until
solid
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010530564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500780A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2008/050986 external-priority patent/WO2009053748A2/en
Publication of JP2011500780A publication Critical patent/JP2011500780A/ja
Publication of JP2011500780A5 publication Critical patent/JP2011500780A5/ja
Pending legal-status Critical Current

Links

JP2010530564A 2007-10-24 2008-10-24 新規結晶形 Pending JP2011500780A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2108MU2007 2007-10-24
PCT/GB2008/050986 WO2009053748A2 (en) 2007-10-24 2008-10-24 Novel crystalline forms

Publications (2)

Publication Number Publication Date
JP2011500780A JP2011500780A (ja) 2011-01-06
JP2011500780A5 true JP2011500780A5 (cg-RX-API-DMAC7.html) 2011-12-08

Family

ID=40262729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530564A Pending JP2011500780A (ja) 2007-10-24 2008-10-24 新規結晶形

Country Status (8)

Country Link
US (1) US8530488B2 (cg-RX-API-DMAC7.html)
EP (1) EP2222649A2 (cg-RX-API-DMAC7.html)
JP (1) JP2011500780A (cg-RX-API-DMAC7.html)
CN (1) CN101939303B (cg-RX-API-DMAC7.html)
AU (1) AU2008315757A1 (cg-RX-API-DMAC7.html)
CA (1) CA2703230A1 (cg-RX-API-DMAC7.html)
NZ (2) NZ585438A (cg-RX-API-DMAC7.html)
WO (1) WO2009053748A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2150547A2 (en) * 2007-05-08 2010-02-10 Generics Ýuk¨Limited Polymorphic forms of bosentan
WO2009004374A1 (en) * 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US8530488B2 (en) * 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
JP5535082B2 (ja) * 2008-01-01 2014-07-02 シプラ・リミテッド ボセンタン、その多形形態及びその塩の合成方法
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
ES2650247T3 (es) 2008-02-08 2018-01-17 Generics [Uk] Limited Procedimiento de preparación del bosentán
EP2331513A1 (en) 2008-08-12 2011-06-15 Cadila Healthcare Limited Process for preparation of bosentan
WO2010061210A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
PL402305A1 (pl) * 2012-12-30 2014-07-07 Instytut Farmaceutyczny Sposób wytwarzania bozentanu w postaci monohydratu o czystości farmaceutycznej

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570699B1 (fr) * 1984-09-24 1987-08-28 Roussel Uclaf Nouveau procede de preparation de derives du 4h-1,2,4-triazole, nouveaux triazoles ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5276004A (en) * 1987-03-20 1994-01-04 Dai Nippon Insatsu Kabushiki Kaisha Process for heat transfer recording
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
EP1535613B1 (en) 1999-11-17 2010-08-25 Teva Pharmaceutical Industries, Ltd. Process for preparing a polymorphic form of atorvastatin calcium
AU779931B2 (en) 1999-12-16 2005-02-17 Teva Pharmaceutical Industries Ltd. Novel processes for making- and a new crystalline form of- leflunomide
DK1254121T3 (da) * 2000-01-25 2006-06-12 Hoffmann La Roche Fremstilling af sulfonamider
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
WO2004076443A1 (en) 2003-02-25 2004-09-10 Hetero Drugs Limited Amorphous form of losartan potassium
US7872019B2 (en) 2003-03-12 2011-01-18 Cadila Healthcare Limited Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
WO2004087660A1 (en) 2003-04-02 2004-10-14 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
US20080188663A1 (en) * 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
US20080242687A1 (en) * 2007-04-02 2008-10-02 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
EP2150547A2 (en) 2007-05-08 2010-02-10 Generics Ýuk¨Limited Polymorphic forms of bosentan
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US20110014291A1 (en) * 2007-10-11 2011-01-20 Actavis Group Ptc Ehf Novel Polymorphs of Bosentan
US8530488B2 (en) * 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
EP2072503B1 (en) * 2007-12-18 2011-10-26 Dipharma Francis S.r.l. Process for the preparation of bosentan
WO2009095933A2 (en) 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
ES2650247T3 (es) 2008-02-08 2018-01-17 Generics [Uk] Limited Procedimiento de preparación del bosentán
EP2268634A2 (en) 2008-03-13 2011-01-05 Actavis Group PTC EHF Processes for the preparation of bosentan and related compounds using novel intermediates
WO2009141167A1 (en) * 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
WO2010061210A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
IT1393136B1 (it) * 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Similar Documents

Publication Publication Date Title
JP2011500780A5 (cg-RX-API-DMAC7.html)
CN103664921B (zh) 一种阿齐沙坦晶型a及其制备方法
CN104860894A (zh) 一种抗心衰药lcz696的制备方法
CN101983195A (zh) 新型多晶型物及其制备方法
JP2019505532A5 (cg-RX-API-DMAC7.html)
US8252805B2 (en) Forms of lapatinib ditosylate and processes for preparation thereof
WO2008135795A2 (en) Polymorphic forms of bosentan
WO2016107289A1 (zh) 制备索非布韦晶型6的方法
CN102639522A (zh) 3-(4-氨基-1-氧代-1, 3-二氢-异吲哚-2-基)-哌啶-2, 6-二酮的固体形式及制备它们的方法
EP2584901A1 (en) A process for etra virine intermediate and polymorphs of etravirine
CN112142604A (zh) 一种盐酸溴己新及其中间体的制备方法
JP2013503173A5 (cg-RX-API-DMAC7.html)
WO2012037764A1 (zh) (e)-2-[2-(6-氯嘧啶-4-基氧)苯基]-3-甲氧基丙烯酸甲酯的制备方法
CN101928277B (zh) 4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]氨基]安息香酸的制备方法、相关中间体及其应用
CN110092786B (zh) 吴茱萸碱的制造方法
CN103360381B (zh) 阿齐沙坦的新晶型及其制备方法和应用
CN103772413B (zh) 一种利福平ⅱ晶型的制备方法
CN112028896A (zh) 阿卡替尼的新晶型及其制备方法
WO2012168948A2 (en) Process for febuxostat
CN102746283A (zh) 高纯度水飞蓟宾的制备方法
WO2024094110A1 (zh) 一种替马他赛化合物晶型及其制备方法和用途
WO2014195977A2 (en) Novel polymorphs of vismodegib
CN102838594A (zh) 一种达沙替尼的制备及精制方法
WO2012038971A2 (en) Novel polymorphs of febuxostat
CN104817546A (zh) 一种奥美沙坦酯母液回收的方法